Melane Sampson, Author at BioTuesdays

Developments

FDA grants Senti RMAT for SENTI-202 in R/R AML

Senti Bio (NASDAQ: SNTI) has announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen...

December 9, 2025

Developments

Formycon, MS partner to commercialize Keytruda biosimilar candidate in MENA region

Formycon AG (FSE: FYB, Prime Standard) and closely held MS Pharma have jointly announced that they have entered into an exclusive licensing and supply agreement for the commercialization of FYB206—Formycon’s biosimilar...

December 9, 2025

Developments

Greenwich completes enrollment of FLAMINGO-01 open label arm

Greenwich LifeSciences (NASDAQ: GLSI) has announced the completion of enrollment in the open label non-HLA-A*02 arm of FLAMINGO-01. FLAMINGO-01 is a Phase III clinical trial designed to evaluate the safety and efficacy...

December 8, 2025

Developments

Moleculin enters agreement with research group to evaluate Annamycin for GBM

Moleculin Biotech (NASDAQ: MBRX) has announced that it has entered into a research and material transfer agreement with non-profit CIC biomaGUNE for preclinical research evaluating Annamycin for the treatment of...

December 8, 2025

Developments

Immutep and Dr. Reddy’s Labs collaborate to commercialize oncology drug

Immutep (ASX: IMM; NASDAQ: IMMP) and Dr. Reddy’s Laboratories (BSE: 500124; NSE: DRREDDY; NYSE: RDY; NSEIFSC: DRREDDY) have announced that they have entered into a strategic collaboration and exclusive licensing...

December 8, 2025

Developments

Stanford’s Dr. Ghanouni receives Cum Laude award for RSNA presentation on CAPTAIN trial of TULSA v robotic radical prostatectomy

Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that Pejman Ghanouni, MD, PhD, associate professor in the Department of Radiology, Division of Body MRI at Stanford University School of Medicine, has received the...

December 5, 2025

Developments

Ekso inks agreement to become exclusive U.S. distributor of MediTouch’s groundbreaking BalanceTutor rehab system

Ekso Bionics Holdings (NASDAQ: EKSO) has announced that it has entered into an agreement with Israel-based closely-held MediTouch (MediTouch) to become the exclusive authorized sales agent and distributor of MediTouch’s...

December 4, 2025

Developments

ADC announces updated data from trial of ZYNLONTA with glofitamab in r/r DLBCL

ADC Therapeutics (NYSE: ADCT) announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI) in...

December 3, 2025

Developments

Black Diamond announces Phase 2 data for silevertinib in 1L NSCLC

Black Diamond Therapeutics (NASDAQ: BDTX) has announced topline data from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with non-classical epidermal growth factor...

December 3, 2025

Developments

Capricor reports positive topline results from Phase 3 study of Deramiocel in DMD

Capricor Therapeutics (NASDAQ: CAPR) has announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel for the treatment of Duchenne muscular dystrophy (DMD). HOPE-3 is a randomized...

December 3, 2025

Author - Melane Sampson

FDA grants Senti RMAT for SENTI-202 in R/R AML

Formycon, MS partner to commercialize Keytruda biosimilar candidate in MENA region

Greenwich completes enrollment of FLAMINGO-01 open label arm

Moleculin enters agreement with research group to evaluate Annamycin for GBM

Immutep and Dr. Reddy’s Labs collaborate to commercialize oncology drug

Stanford’s Dr. Ghanouni receives Cum Laude award for RSNA presentation on CAPTAIN trial of TULSA v robotic radical prostatectomy

Ekso inks agreement to become exclusive U.S. distributor of MediTouch’s groundbreaking BalanceTutor rehab system

ADC announces updated data from trial of ZYNLONTA with glofitamab in r/r DLBCL

Black Diamond announces Phase 2 data for silevertinib in 1L NSCLC

Capricor reports positive topline results from Phase 3 study of Deramiocel in DMD

Subscribe